ClinicalTrials.gg

Program

Meribatinib

Also written as “TGRX-678” and “[14C]TGRX-678”.

Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, led by 2 companies.

Furthest: phase 3, since Mar 18, 20266 company-led studies, 4 open or runningNext primary completion: Dec 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen TargetRx32 open or runningphase 3since Mar 18, 2026Oct 8, 2023Dec 31, 2027phase 1 · NCT06088888
Shenzhen TargetRx32 open or runningphase 2since May 28, 2024May 23, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2022First study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Shenzhen TargetRxShenzhen TargetRx · NCT05434312 · 90 enrolled · China
  2. Oct 8, 2023Shenzhen TargetRx's first study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNew to Shenzhen TargetRxShenzhen TargetRx · NCT06088888 · 90 planned · United States
  3. May 28, 2024Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT06453902 · 40 planned · China
  4. Nov 18, 2024Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT06697899 · 76 enrolled · China
  5. May 15, 2025Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT06986772 · 6 enrolled · China
  6. Mar 18, 2026Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositivePhase 3 reachedShenzhen TargetRx · NCT07489755 · 180 planned

Ahead

  1. Dec 31, 2027Primary completion: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT06088888
  2. May 1, 2030Primary completion: phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveShenzhen TargetRx · NCT07489755

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07489755Leukemia, Myelogenous, Chronic, BCR-ABL Positive3Not yet recruitingShenzhen TargetRxMay 1, 2030180
NCT06986772Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China1CompletedShenzhen TargetRxAug 17, 20256
NCT06697899Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China1CompletedShenzhen TargetRxJan 6, 202576
NCT06453902Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China2RecruitingShenzhen TargetRxJun 30, 202640
NCT06088888Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States1RecruitingShenzhen TargetRxDec 31, 202790
NCT05434312Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China1Active, not recruitingShenzhen TargetRxMar 202690

How it is read

Names in the registry

  • “TGRX-678”, 5 entries
  • “[14C]TGRX-678”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Meribatinib (Shenzhen TargetRx): development program | ClinicalTrials.gg